DiaCarta Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- DiaCarta's estimated annual revenue is currently $6.7M per year.
- DiaCarta received $45.0M in venture funding in February 2018.
- DiaCarta's estimated revenue per employee is $155,000
- DiaCarta's total funding is $53M.
- DiaCarta has 43 Employees.
- DiaCarta grew their employee count by 10% last year.
- DiaCarta currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Advanced Cell D...||$27.6M||178||8%||N/A|
|The J. Craig Ve...||$33.3M||215||N/A||N/A|
What Is DiaCarta?
DiaCarta is a translational genomics and personalized diagnostics company that provides ultra-sensitive detection tools for cancer diagnosis, therapy identification and prognosis monitoring. Our mission is to provide ultra-sensitive and advanced technologies that will redefine the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world. To learn more, visit http://www.diacarta.com.keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals
Number of Employees
Employee Growth %
|Yulei Shang||Production Manager||Email Available|
|Elena Peletskaya||Director, Molecular Analytics, Juno Therapeutics|
|Aiguo Zhang||Founder, President & CEO||Email Available|
|Michael Powell||Chief Scientific Officer||Email Available|
|Nitin Udar||Sr. Vp Diagnostics And Regulatory||Email Available|
|Ray Meng||Senior Manager, Product Managment And System Integration||Email Available|
|Effie Ho||General Manager||Email Available|
|Claudia Li||Manager Of Digital Marketing And Marketing Communication||Email Available|
|Wei Liu||Sr. Dir of Product Management & Marketing||Email Available|
|Jinwei Du||Manager, IVD Development||Email Available|
BUSINESS WIRE)--DIACARTA, Inc., a precision diagnostic company and leading developer of products for nucleic acid-based detection ...
RICHMOND, Calif.--(BUSINESS WIRE)--DiaCarta today announced that CIO Bulletin has named it among the 30 Fastest Growing Companies ...
NEW YORK (GenomeWeb) – DiaCarta said today that it has completed a Series B funding round, raising a total of $45 million. The second ...
|2018-02-13||$45.0M||B||Fortune Fountain Capital||Article|